Protective effects for PCSK9 were noted with respect to abdominal aortic aneurysms (OR = 0.54, 95% CI = 0.36–0.81, p = 2.74 × 10−3) and lower extremity artery aneurysms (OR = 0.12, 95% CI = 0.04–0.4, p = 5.52 × 10−4); however, the meta-analysis revealed a higher risk of cerebral aneurysm with respect to genetically proxied PCSK9 inhibition (OR = 1.6, 95% CI = 1.07–2.41, p = 0.02). The gene discussed is PCSK9; the disease is aneurysm.